Company / R&D Expense
enGene Holdings Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$94.5M
FY2025
5-year range
$15.5M / $94.5M
FY2022-FY2025
Trend
+146.6%
vs FY2024
Sector context
#142 of 208
Health Care
What the data says
At $94M, enGene Holdings Inc.'s r&d expense ranks #142 of 208 in the Health Care sector. R&D Expense has increased for 3 consecutive years, from $15M in FY2022 to $94M in FY2025.
Based on SEC 10-K filings.
$94M in FY2025 with a 3-year CAGR of +82.8%.
Improved from $16M to $94M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +82.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#142 of 208 in Health CareTop 68% of 208This company $94.5M Sector average $644.3M
▼
-85.3% below sector average
Key checks
Key Insights
- enGene Holdings Inc.'s r&d expense has grown for 3 consecutive years.
- 3-year CAGR of +82.8%, indicating consistent growth.
- In FY2025, r&d expense increased 146.6% year-over-year.
- Ranks #142 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.13 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $94.5M | +146.6% |
| FY2024 | $38.3M | +132.8% |
| FY2023 | $16.5M | +6.4% |
| FY2022 | $15.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026